Greenwich LifeSciences has secured acceptance of two abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting scheduled for April 17-22, 2026. One of the accepted abstracts marks a milestone as the first presentation to be co-authored with the complete FLAMINGO-01 Steering Committee, reflecting collaborative progress on the company's Phase III clinical trial program.
The Phase III FLAMINGO-01 trial's non-HLA-A*02 arm has achieved full enrollment with 250 patients, representing a significant enrollment milestone for the study. Preliminary data from the trial demonstrates approximately 80% reduction in recurrence rates following the Primary Immunization Series, findings that align with efficacy signals observed in the preceding Phase IIb trial results.
The upcoming AACR presentation will provide the research community with detailed findings from the pivotal trial, which evaluates the company's therapeutic candidate in cancer treatment. This conference appearance underscores Greenwich LifeSciences' progress in advancing its clinical pipeline and contributes to the broader oncology research dialogue at one of the field's premier annual gatherings.